MItral Regurgitation Risk Assessment and CLinical modElling
Recruiting · NCT06876883 · Observational (researchers observe without assigning treatment) · Lead sponsor: Sun Yat-sen University
View the official record on ClinicalTrials.gov →What this trial is about
Mitral regurgitation (MR) is a common valvular heart disease worldwide, and untreated severe MR is associated with an elevated risk of heart failure and mortality. According to causes, MR could be divided into primary or secondary MR. The risk factors of mortality or heart failure hospitalization in different types of MR patients are under intensive investigation. MItral Regurgitation risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study including adult patients diagnosed with ≥ moderate MR during hospitalization. Comprehensive echocardiographic examination was conducted at baseline evaluating valvular heart disease severity, atrial and ventricular systolic/diastolic function, pulmonary artery systolic pressure (PASP), etc. We aim to evaluate the prognostic risk factors of patients with MR and construct a prognostic clinical model to guide clinical decision-making.
Who can take part
Inclusion criteria
- Patients diagnosed with ≥ moderate mitral regurgitation during hospitalization.
- Aged over 18 yrs.
Exclusion criteria
- Patients unable to provide written consent.
Where it is running
1 location listed.
- The First Affiliated Hospital of Sun Yat-sen Univerity - Guangzhou, Guangdong, China